Based on the forecasted data for Antihypertensive Medicine Sales in Canada:
- 2024: 128.3 million CAD
- 2025: 129.1 million CAD
- 2026: 129.8 million CAD
- 2027: 130.3 million CAD
- 2028: 130.7 million CAD
Year-on-year variations:
- 2025: 0.62%
- 2026: 0.54%
- 2027: 0.39%
- 2028: 0.31%
Compound Annual Growth Rate (CAGR) over the 5-year period (from 2024 to 2028): 0.46%
Future Trends to Watch: The sales of antihypertensive medicines in Canada are projected to grow modestly through 2028. While the growth rate is relatively slow, the steady increase suggests a stable market. Factors such as aging population, advancements in treatment options, and increased awareness about hypertension management might contribute to this trend. Monitoring ongoing healthcare policies and emerging technologies will be essential for a comprehensive market strategy.
